SCHEMBL5564220

SCHEMBL5564220

C=C(C(=O)c1ccc(S(=O)(=O)NCCCn2ccnc2)cc1)c1cc(-c2cccs2)c(OC)cc1OC

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 5/20 0.51
▸ POLB P06746 2/20 0.51
▸ ALDH1A1 P00352 2/20 0.47
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42
▸ RELA Q04206 1/20 0.42
▸ KMT2A Q03164 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ GLA P06280 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5564223 0.83 CYP19A1 (0.51) CYP19A1POLBALDH1A1CYP3A4CYP2C9
SCHEMBL5564227 0.83 CYP19A1 (0.51) CYP19A1POLBALDH1A1CYP3A4CYP2C9
SCHEMBL5564402 0.83 CYP19A1 (0.49) CYP19A1POLBALDH1A1KMT2ANAMPT
SCHEMBL5566864 0.81 CYP19A1 (0.53) CYP19A1POLBALDH1A1CYP3A4CYP2C9
SCHEMBL5559874 0.81 CYP19A1 (0.51) CYP19A1POLBALDH1A1KMT2A
SCHEMBL5560851 0.80 L3MBTL1 (0.39) POLBALDH1A1KDM4EKMT2A
SCHEMBL5566144 0.80 ALDH1A1 (0.45) POLBALDH1A1KDM4EKMT2A
SCHEMBL5564885 0.80 PKM (0.49) ALDH1A1LMNAKMT2ANAMPT
SCHEMBL5566988 0.80 KMT2A (0.51) POLBALDH1A1KDM4ELMNARAB9A
SCHEMBL5566178 0.79 TNFRSF1A (0.39) POLBALDH1A1KDM4ELMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 — — US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 — — US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 — — US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 — — WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 — — US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 — — US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 — — US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CYP19A1 169/4885POLB 4214/4885ALDH1A1 1653/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 CYP19A1 169/4885POLB 4214/4885ALDH1A1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback